Review
doi: 10.1016/j.tips.2005.10.001.
Epub 2005 Oct 21.
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis
Affiliations
- PMID: 16243403
- DOI: 10.1016/j.tips.2005.10.001
Item in Clipboard
Review
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis
Trends Pharmacol Sci.
2005 Dec.
Abstract
Atherosclerosis is a chronic disease of the vasculature that is influenced by multiple factors that involve a complex interplay between some components of the blood and the arterial wall. Inflammation and oxidative stress have key roles in atherogenesis. The production of F2-isoprostanes (F2-IPs), thromboxane A2 (TxA2) and prostacyclin (PGI2) increases in atherosclerosis, and recent studies show that pharmacological modulation of their biosynthesis and biological activities are important therapeutic targets for managing atherosclerosis. In this review, we highlight recent breakthroughs in the roles of F2-IPs, TxA2 and PGI2 in atherogenesis, and identify pertinent therapeutic targets.
Similar articles
-
Vascular biology of eicosanoids and atherogenesis.Expert Rev Cardiovasc Ther. 2009 Sep;7(9):1079-89. doi: 10.1586/erc.09.91. Expert Rev Cardiovasc Ther. 2009. PMID: 19764861 Review.
-
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.Circulation. 2005 Jan 25;111(3):334-42. doi: 10.1161/01.CIR.0000153386.95356.78. Epub 2005 Jan 17. Circulation. 2005. PMID: 15655126
-
Changes in prostacyclin, thromboxane A2 and F2-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia.Immunopharmacology. 1999 Oct 15;44(1-2):193-8. doi: 10.1016/s0162-3109(99)00137-x. Immunopharmacology. 1999. PMID: 10604544
-
Prostanoid and isoprostanoid pathways in atherogenesis.Atherosclerosis. 2008 Nov;201(1):8-16. doi: 10.1016/j.atherosclerosis.2008.04.037. Epub 2008 Apr 29. Atherosclerosis. 2008. PMID: 18514200 Review.
-
Prostanoids as pharmacological targets in COPD and asthma.Eur J Pharmacol. 2006 Mar 8;533(1-3):89-100. doi: 10.1016/j.ejphar.2005.12.058. Epub 2006 Feb 3. Eur J Pharmacol. 2006. PMID: 16458293 Review.
Cited by
-
Relation of smoking status to a panel of inflammatory markers: the framingham offspring.Atherosclerosis. 2008 Nov;201(1):217-24. doi: 10.1016/j.atherosclerosis.2007.12.058. Epub 2008 Mar 4. Atherosclerosis. 2008. PMID: 18289552 Free PMC article.
-
Common genetic variation, residential proximity to traffic exposure, and left ventricular mass: the multi-ethnic study of atherosclerosis.Environ Health Perspect. 2010 Jul;118(7):962-9. doi: 10.1289/ehp.0901535. Epub 2010 Mar 22. Environ Health Perspect. 2010. PMID: 20308035 Free PMC article.
-
Prostanoid receptor antagonists: development strategies and therapeutic applications.Br J Pharmacol. 2009 Sep;158(1):104-45. doi: 10.1111/j.1476-5381.2009.00317.x. Epub 2009 Jul 15. Br J Pharmacol. 2009. PMID: 19624532 Free PMC article. Review.
-
Pro-inflammatory prostaglandins and progression of colorectal cancer.Cancer Lett. 2008 Aug 28;267(2):197-203. doi: 10.1016/j.canlet.2008.03.004. Epub 2008 Apr 11. Cancer Lett. 2008. PMID: 18406516 Free PMC article. Review.
-
An insight into the potentially old-wonder molecule-quercetin: the perspectives in foresee.Chin J Integr Med. 2015 Sep 9:1-16. doi: 10.1007/s11655-015-2073-x. Online ahead of print. Chin J Integr Med. 2015. PMID: 26354747 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
